Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Prior to Biogen he was CEO at ZymoGenetics and led its acquisition ... I look forward to working with the talented Climb Bio ...

Biogen Inc.'s stock shed early gains to trade ... Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors ...

“At Biogen Digital Health we have a full team dedicated to patient experience and user insights,” he said. “Their mission is to start from the need, improve the experience, and iterate.

Biopharma Leaders of Color (BLOC), a 501(c)(3) non-profit organization dedicated to promoting the professional advancement of people of color and growing the representation of leaders from ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of ...

Satellos Bioscience Inc.(TSX: MSCL) (OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle ...

A SleepScore Labs scientific validation study revealed that Rebalance Health Systems delivers significant improvements in sleep, with research participants experiencing faster sleep onset, fewer ...

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unm ...

Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...